在良性前列腺增生症的医疗管理中的风险和副作用
Abdulghafour Halawani1,2, Ryan Paterson2, Tianshuang Zhong2
1Department of Urology, King Abdulaziz University, Jeddah, Saudi Arabia.
Prostate international
|July 22, 2024
概括
良性前列腺增生症 (BPH) 影响了许多男性,导致尿道问题. 本综述详细介绍了常见的BPH药物的风险和副作用,以帮助明智的治疗选择.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
背景情况:
- 良性前列腺增生症 (BPH) 非常普遍,影响男性的生活质量.
- BPH导致膀外流阻塞和下泌尿道症状.
- 第一线治疗包括改变生活方式和药物治疗.
研究的目的:
- 审查常见BPH药物的风险和副作用.
- 通知临床医生和患者关于与药物相关的不良事件.
- 支持BPH管理的知情决策.
主要方法:
- 对BPH的药理疗法的文献综述.
- 对α抑制剂,5α-减少酶抑制剂,5固酶-5抑制剂,抗胆固醇剂,B3激动剂和德斯莫普林素报告的副作用的分析.
主要成果:
- 常见的BPH药物虽然有效,但具有显著的副作用概况.
- 了解这些副作用对于患者的坚持和治疗成功至关重要.
- 个人药物风险各不相同,需要仔细考虑.
结论:
- 对药物风险和益处的知情讨论对于BPH治疗至关重要.
- 临床医生和患者必须权衡潜在的副作用与治疗结果.
- 本综述为优化BPH药物治疗提供了基础.
相关概念视频
Disorders of the Male Reproductive System
377
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
377
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
617
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
617
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
150
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
150
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
632
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
632
Antiasthma Drugs: β2-Adrenoceptor Agonists
245
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
245
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165


